Flow Cytometry is an important analytical and cell purification tool in cancer and immunological research. Modern cancer analysis requires innovative procedures that include both imaging methods and non-imaging analysis, such as that provided by flow cytometry. Flow cytometry allows the isolation of pure cell populations comprising less than 0.01% of a complex mixture. In addition, as an analytical tool it permits statistical analysis of cell population and cell function changes, apoptosis, intracellular protein expression, and gene transfection for example. Innovative methods that contribute to modern cancer research include gene expression detection with green fluorescent protein, parameter cytometry, apoptotic effect of chemotherapy, multi-drug resistance evaluation, and minimal residual disease detection. In addition, the integrated use of cell isolation (by flow cytometry) and downstream assessment of isolated cells (by proteomics or genomics) offers a powerful application of technologies offered by multiple Resources within the Knight Cancer Institute. High quality instrumentation is available to Knight Cancer Institute members in the form of two cell sorters and three analytical instruments. The Flow Cytometry Shared Resource provides consultation, training/teaching, technical expertise, and technical services in flow cytometry to meet the needs of Knight Cancer Institute members.

Public Health Relevance

The Flow Cytometry Shared Resource offers state of the art equipment and support to Knight Cancer Institute researchers studying a wide array of human diseases. The resource positively impacts the study of hematopoietic and non-hematopoietic cancers, infectious diseases, inflammatory diseases, autoimmune diseases, and graft versus host disease;as well as stem cell biology and regenerative medicine.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
United States
Zip Code
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028

Showing the most recent 10 out of 277 publications